EuBiologics Co., Ltd. (KOSDAQ:206650)

South Korea · Delayed Price · Currency is KRW

9,080.00

-70.00 (-0.77%)

Aug 11, 2026, 2:24 PM KST

EuBiologics Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	96,035	96,035	69,366	55,467	39,385	28,490
Revenue Growth	62.39%	38.45%	25.06%	40.83%	38.24%	-
Gross Profit	96,035	96,035	33,961	23,549	15,218	6,899
Operating Income	34,321	34,321	7,699	-3,769	-7,230	-5,962
Net Income	24,866	24,866	-13,879	-1,099	-27,574	-60,134
Earnings Per Share	-	-	-381.00	-30.19	-778.00	-2146.27
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
South Korea	2,507	4,471	4,421	4,155
Overseas	66,859	50,996	34,964	24,335
Total	69,366	55,467	39,385	28,490

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	-	-	11,491	11,224	31,673	54,874
Total Debt	-	-	14,779	15,663	15,521	22,571
Net Cash (Debt)	-	-	-3,287	-4,439	16,152	32,303
Net Cash Growth	-	-	-	-	-50.00%	-
Net Cash Per Share	-	-	-90.19	-121.93	455.63	1152.93

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-	-	26,452	6,440	-7,602	1,659
Capital Expenditures	-	-	-6,936	-9,066	-6,595	-8,030
Free Cash Flow	-	-	19,515	-2,626	-14,196	-6,371
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Gross Margin	100.00%	100.00%	48.96%	42.45%	38.64%	24.22%
Operating Margin	35.74%	35.74%	11.10%	-6.79%	-18.36%	-20.93%
Pretax Margin	24.77%	24.77%	-21.07%	-6.02%	-78.25%	-212.69%
Profit Margin	25.89%	25.89%	-20.01%	-1.98%	-70.01%	-211.07%
FCF Margin	-	-	28.13%	-4.74%	-36.05%	-22.36%

Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '26 Aug 11, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
PE Ratio	13.52	17.85	-	-	-	-
P/FCF Ratio	17.23	-	21.43	-	-	-
PS Ratio	3.50	4.62	6.03	5.85	32.28	23.01